Regeneron Pharma (REGN)
$625.93
11.44 (1.83%)
REGN Stock Quote Delayed 30 Minutes
7 Stocks That Usually Benefit From a Recession
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$635.83
Market Cap
69.68B
PE Ratio
16.33
EPS
38.3368
Volume (Avg. Vol.)
536,104
Day's Range
$631.45 - $642.97
52-Week Range
$629.02 - $1,209.71
Dividend & Yield
$0.88 (0.14%)
REGN Stock Predictions, Articles, and Regeneron Pharma News
3 Standout Stocks to Buy for the Next Bull Market
These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen.
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
These founder-led companies are at the forefront of industry innovation, and historical trends indicate that they will likely outperform.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
7 High Priced Stocks That Would Benefit From a Stock Split
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names.
3 Biotech Stocks That Could Make Your Grandchildren Rich
These biotech stocks are poised to generate significant returns to investors due to their high growth potential.
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package.
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN).
